Switch theme
Sign up to access all valuation multiples
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
2004
11
LTM Revenue $124M
LTM EBITDA $88.7M
$814M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neuren Pharma has a last 12-month revenue of $124M and a last 12-month EBITDA of $88.7M.
In the most recent fiscal year, Neuren Pharma achieved revenue of $147M and an EBITDA of $126M.
Neuren Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neuren Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.2M | $147M | XXX | XXX | XXX |
| Gross Profit | n/a | $9.2M | XXX | XXX | XXX |
| Gross Margin | NaN% | 6% | XXX | XXX | XXX |
| EBITDA | -$1.0M | $126M | XXX | XXX | XXX |
| EBITDA Margin | -11% | 86% | XXX | XXX | XXX |
| Net Profit | -$4.9M | $0.1M | XXX | XXX | XXX |
| Net Margin | -54% | 0% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Neuren Pharma's stock price is AUD 12 (or $7).
Neuren Pharma has current market cap of AUD 1.5B (or $955M), and EV of AUD 1.3B (or $814M).
See Neuren Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $814M | $955M | XXX | XXX | XXX | XXX | $0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Neuren Pharma has market cap of $955M and EV of $814M.
Neuren Pharma's trades at 6.6x LTM EV/Revenue multiple, and 9.2x LTM EBITDA.
Analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Neuren Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $814M | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.5x | XXX | XXX | XXX |
| P/E | 9.6x | XXX | XXX | XXX |
| P/E/Growth | -0.2x | XXX | XXX | XXX |
| EV/FCF | 7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNeuren Pharma's NTM/LTM revenue growth is -55%
Neuren Pharma's revenue per employee for the last fiscal year averaged $13.3M, while opex per employee averaged $1.9M for the same period.
Over next 12 months, Neuren Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Neuren Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1494% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 86% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12583% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 31% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $13.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 14% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuren Pharma acquired XXX companies to date.
Last acquisition by Neuren Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Neuren Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Neuren Pharma founded? | Neuren Pharma was founded in 2004. |
| Where is Neuren Pharma headquartered? | Neuren Pharma is headquartered in Australia. |
| How many employees does Neuren Pharma have? | As of today, Neuren Pharma has 11 employees. |
| Who is the CEO of Neuren Pharma? | Neuren Pharma's CEO is Mr. Jonathan Pilcher. |
| Is Neuren Pharma publicy listed? | Yes, Neuren Pharma is a public company listed on ASX. |
| What is the stock symbol of Neuren Pharma? | Neuren Pharma trades under NEU ticker. |
| When did Neuren Pharma go public? | Neuren Pharma went public in 2005. |
| Who are competitors of Neuren Pharma? | Similar companies to Neuren Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neuren Pharma? | Neuren Pharma's current market cap is $955M |
| What is the current revenue of Neuren Pharma? | Neuren Pharma's last 12-month revenue is $124M. |
| What is the current EBITDA of Neuren Pharma? | Neuren Pharma's last 12-month EBITDA is $88.7M. |
| What is the current EV/Revenue multiple of Neuren Pharma? | Current revenue multiple of Neuren Pharma is 6.6x. |
| What is the current EV/EBITDA multiple of Neuren Pharma? | Current EBITDA multiple of Neuren Pharma is 9.2x. |
| What is the current revenue growth of Neuren Pharma? | Neuren Pharma revenue growth between 2023 and 2024 was 1494%. |
| Is Neuren Pharma profitable? | Yes, Neuren Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
